Integer Holdings Corp (ITGR) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Integer Holdings Corp (ITGR) stock forecast summary
Our AI ranks Integer Holdings Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Integer Holdings Corp is a mid-cap company with a market capitalization of $4.31B. It ranks number 2 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast. Its P/E Ratio of 49.88x is the highest of the 10 peers that report one.
For ITGR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 52.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 33.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ITGR included.
Follow ITGR freeITGR price chart and AI forecast
How ITGR ranks among 5184 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Integer Holdings Corp (ITGR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | ITGR | Rank |
|---|---|---|
| Market Cap | $4.31B | 2/30 |
| P/E Ratio | 49.88x | 1/10 |
| P/B Ratio | 2.51x | 14/23 |
| EPS | $2.54 | – |
| Book Value/Share | $50.56 | – |
| Revenue/Share | $54.23 | – |
| FCF/Share | $3.29 | – |
Profitability & Margins
| Metric | ITGR | Rank |
|---|---|---|
| ROE | 7.5% | 8/19 |
| ROA | 3.8% | 7/24 |
| ROIC | 5.6% | 10/23 |
| Gross Margin | 25.7% | 24/27 |
| Operating Margin | 9.7% | 6/28 |
| Net Margin | 7.0% | 8/22 |
| EBT Margin | 7.4% | 7/28 |
| Tax Rate | 5.9% | – |
Financial Health
| Metric | ITGR | Rank |
|---|---|---|
| Current Ratio | 3.73x | 10/30 |
| Quick Ratio | 2.41x | 12/29 |
| D/E Ratio | 0.99x | 9/25 |
| Financial Leverage | 1.99x | 9/25 |
| Interest Coverage | 1.7x | 9/30 |
| Working Capital | $593M | 3/29 |
Cash Flow
| Metric | ITGR | Rank |
|---|---|---|
| Operating Cash Flow | $205M | 3/30 |
| Free Cash Flow | $112M | 3/14 |
| Capital Spending | -$93M | 12/14 |
| OCF Growth YoY | -2.1% | 8/9 |
| FCF Growth YoY | -7.1% | 4/6 |
| FCF/Sales | 6.1% | 5/14 |
| CapEx/Sales | 5.1% | 3/14 |
Operational Efficiency
| Metric | ITGR | Rank |
|---|---|---|
| Asset Turnover | 0.54x | 11/19 |
| Receivables Turnover | 5.4x | 14/20 |
| Inventory Turnover | 4.8x | 6/27 |
| Fixed Assets Turnover | 3.5x | 17/20 |
| Days Sales Outstanding | 67 days | 7/20 |
| Days Inventory | 77 days | 22/27 |
| Payables Period | 30 days | 20/24 |
| Cash Conversion Cycle | 114 days | 10/19 |
Income Statement
| Metric | ITGR | Rank |
|---|---|---|
| Total Revenue | $1.84B | 2/19 |
| Operating Income | $179M | 3/30 |
| Net Income | $128M | 5/24 |
| R&D Expense | $49M | 5/28 |
| SG&A Expense | $224M | 6/26 |
| Cost of Goods Sold | $1.37B | 2/27 |
Dividend & Shareholder Information
| Metric | ITGR | Rank |
|---|---|---|
| Shares Outstanding | 34M | – |
| Net Income Growth | 55.3% | 2/5 |
| EPS Growth | -27.8% | 4/7 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $811M | 23.7% of assets |
| Cash & Short-term Investments | $21M | 0.6% of assets |
| Accounts Receivable | $339M | 9.9% of assets |
| Inventory | $288M | 8.4% of assets |
| Total Liabilities | $1.70B | 49.8% of assets |
| Short-term Debt | $105M | 3.1% of assets |
ITGR quarterly financials and insider trading
Integer Holdings Corp (ITGR) industry peers
Companies classified under the same SEC industry code as Integer Holdings Corp (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| MDT Medtronic Plc | ▼ | $121.20B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| CBLL Ceribell, Inc. | ▲ | $961M |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $327M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| VANI Vivani Medical, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $75M |
| OM Outset Medical, Inc. | ▲ | $74M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| VASO Vaso Corp | ▲ | $51M |
| POSC Positron Corp | ▲ | $51M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| POCI Precision Optics Corporation, Inc. | ▲ | $34M |
| ITOC Itonic Holdings Ltd | ▼ | $28M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where ITGR sits on the market map
Integer Holdings Corp (ITGR) stock news
Loading...
Integer Holdings Corp (ITGR) stock forecast FAQ
What is the Integer Holdings Corp (ITGR) stock forecast?
Our AI ranks Integer Holdings Corp outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Integer Holdings Corp stock predictions?
For ITGR, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 52.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 33.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Integer Holdings Corp forecasts updated?
Integer Holdings Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Integer Holdings Corp's industry peers?
32 issuers in our coverage, ITGR included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN), Conmed Corp (CNMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.